INCY vs. NVS: Incyte vs. Novartis Stock Comparison

Company Profile

Incyte (INCY) and Novartis (NVS) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but INCY is classified in Biotechnology while NVS is classified in Pharmaceuticals.

Incyte (INCY) trades as ordinary local shares, while Novartis (NVS) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Incyte (INCY) at 7.84% and Novartis (NVS) at 24.33% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

For every dollar of sales, both Incyte (INCY) at 6.71% and Novartis (NVS) at 17.49% retain more as net profit than most peers, landing in the top net margin quartile of their industries.

Both Incyte (INCY) at 33.72% and Novartis (NVS) at 34.27% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Incyte (INCY) at 21.22% and Novartis (NVS) at 9.57% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Incyte (INCY) at 4,173.33% clears its industry range for EPS growth, a much stronger earnings trajectory than Novartis (NVS) at 21.81%, which is closer to a typical peer reading.

Growth Metrics

Financial Strength

Incyte (INCY) at 3.84 keeps current ratio within its industry’s typical mid-range, while Novartis (NVS) at 0.88 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for NVS.

Incyte (INCY) at 0.01 keeps leverage in the lower quartile, while Novartis (NVS) at 1.29 sits in the higher-leverage quartile.

Financial Strength Metrics

Dividends

Incyte (INCY) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Novartis (NVS) reports a yield of 2.88%, ranking against industry peers normally.

Incyte (INCY) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Novartis (NVS) reports a payout of 90.46%, ranking against industry peers normally.

Dividend Metrics

Valuation

Novartis (NVS) at 31.02 is near its industry’s usual P/E ratio, while Incyte (INCY) at 61.05 sits in the richer quartile — INCY needs stronger growth or earnings quality to justify the premium.

On P/S ratio, both Incyte (INCY) at 4.06 and Novartis (NVS) at 5.35 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Incyte (INCY) at 4.33 is valued about in line with its industry on P/B ratio, while Novartis (NVS) at 8.25 carries an above-peer premium to book — NVS is pricier on assets.

Valuation Metrics